473 related articles for article (PubMed ID: 24026560)
1. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.
Groop PH; Cooper ME; Perkovic V; Emser A; Woerle HJ; von Eynatten M
Diabetes Care; 2013 Nov; 36(11):3460-8. PubMed ID: 24026560
[TBL] [Abstract][Full Text] [Related]
2. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Groop PH; Cooper ME; Perkovic V; Hocher B; Kanasaki K; Haneda M; Schernthaner G; Sharma K; Stanton RC; Toto R; Cescutti J; Gordat M; Meinicke T; Koitka-Weber A; Thiemann S; von Eynatten M
Diabetes Obes Metab; 2017 Nov; 19(11):1610-1619. PubMed ID: 28636754
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
Thrasher J; Kountz DS; Crowe S; Woerle HJ; von Eynatten M
Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Huisman H; Jones R; von Eynatten M; Patel S; Woerle HJ
Lancet; 2013 Oct; 382(9902):1413-23. PubMed ID: 23948125
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Owens DR; Swallow R; Dugi KA; Woerle HJ
Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
12. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.
Cooper ME; Perkovic V; Groop PH; Hocher B; Hehnke U; Meinicke T; Koitka-Weber A; van der Walt S; von Eynatten M
J Hypertens; 2019 Jun; 37(6):1294-1300. PubMed ID: 30540657
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ
Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ
Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
[TBL] [Abstract][Full Text] [Related]
17. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
Forst T; Uhlig-Laske B; Ring A; Ritzhaupt A; Graefe-Mody U; Dugi KA
Diabetes Obes Metab; 2011 Jun; 13(6):542-50. PubMed ID: 21352464
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin: from bench to bedside.
Doupis J
Drug Des Devel Ther; 2014; 8():431-46. PubMed ID: 24851042
[TBL] [Abstract][Full Text] [Related]
19. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
